PA-TELEFLEX
11.3.2021 08:02:06 CET | Business Wire | Press release
Teleflex Incorporated (NYSE: TFX)– Men in France living with Benign Prostatic Hyperplasia (BPH), a condition in which the prostate enlarges as men get older and can cause significant discomfort, will now be offered a newly available minimally invasive treatment on the public health care system, the UroLift® System. The proven procedure, developed by medical technology provider Teleflex to treat lower urinary tract symptoms due to BPH, is now reimbursable under French mandatory health insurance for the first time.
Following a positive Haute Autorité de Santé (HAS) assessment, a procedure code has been granted allowing hospitals to offer the UroLift System to men over 50 years of age who show symptoms of an enlarged prostate up to 100cc. † Approximately 250,000 people have already been treated with the device worldwide* and it is estimated that, in France, between 3,400 and 6,900 patients could benefit from the procedure each year.1
Unlike more invasive surgical treatments and prescription medicines which can lead to erectile or ejaculatory dysfunction, the UroLift System is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction, while being safe and effective.2,3,4, It has demonstrated a more positive impact on quality of life than reported for patients on pharmaceutical medications. 2,3
In those living with BPH, the prostate can press on and block the urethra, potentially causing an urgent need to urinate, and a need to urinate frequently, among other symptoms. It is estimated that almost two million men live with the condition in France.5 The UroLift permanent implants, delivered during an outpatient procedure, can relieve prostate obstruction without cutting, heating, or removing prostate tissue. Patients typically can return home the same day without a catheter and experience rapid symptom relief and recovery with low complication rates.6,7
Matt Wiggins, Interventional Urology General Manager, EMEA, said: “Today’s decision means men in France finally have a safe and effective treatment option which does not compromise on sexual function.**2 As patients can be treated with the UroLift System in an ambulatory setting, rather than a classical operating theatre, and allows patients to be discharged quickly, usually without a catheter, it gives French urologists a new way to relieve some of the pressure on resources caused by the COVID-19 pandemic and pause on elective surgeries.6,7 The UroLift System has the potential to save hours of theatre time and bed days, while reducing complications and waiting lists, making it a timely alternative for those wishing to ease the strain on current services.8,9 ”
About the UroLift® System
The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 50 years or older. As with any medical procedure, individual results may vary. The UroLift permanent implants, delivered during an outpatient procedure, relieve prostate obstruction without cutting, heating, or removing prostate tissue. The UroLift System is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction in the L.I.F.T pivotal study.1 Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.1 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information. The Prostatic Urethral Lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. Approximately 200,000 men have been treated with the UroLift System in select markets worldwide.* As with any medical procedure, individual results may vary. Learn more at www.UroLift.com .
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com .
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com .
Teleflex is the home of Arrow® , Deknatel® , Hudson RCI® , LMA® , Pilling® , Rusch® , UroLift® System and Weck® – trusted brands united by a common sense of purpose.
MAC01749-02 Rev A:
* Management estimate based on product sales and average units per procedure
** No instances of new onset, sustained erectile or ejaculatory dysfunction in the L.I.F.T pivotal study
† Contraindications: The UroLift System should not be used if the patient has; a prostate volume >100cc, a urinary tract infection
1. https://www.has-sante.fr/upload/docs/evamed/CNEDIMTS-6011_UROLIFT_05_novembre_2019_(6011)_avis.pdf
2. Roehrborn et al. Can J Urol 2017
3. AUA Guidelines 2003
4. McVary, J Sex Med 2014
5. NeoTract OUS Market Model estimates for 2021
6. Shore, Can J Urol 2014
7. Roehrborn, J Urology 2013
8. Orlowski ISPOR 2018
9. NICE Shared Learning Case Study – UroLift Norfolk and Norwich NHS Trust. 2016
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005798/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Only 7% of Companies Achieve Full Compliance as Global Expansion Increases Legal Complexity11.5.2026 15:00:00 CEST | Press release
47% of general counsels say beneficial ownership rules pose the biggest risks to legal operations44% lack confidence in meeting cross-border data security requirements As businesses accelerate their global expansion in 2026, compliance fails to keep pace. In fact, only 7% of organizations report full compliance across their global entities, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 350 general counsel (GCs) and senior legal professionals across Europe, North America, and Asia Pacific to examine how their teams navigate international expansion, regulatory pressure, and the increasing adoption of artificial intelligence (AI).¹ The findings appear in CSC’s latest report, General Counsel Barometer 2026: From Complexity to Control. Most organizations report partial compliance, with over half (53%) estimating they are 50–75% compliant, and a further 35% placing themselves between 76%–99%. This leaves just 7%
IFF Opens Vanilla Innovation Center in Madagascar11.5.2026 14:15:00 CEST | Press release
Advancing science‑led flavor innovation where vanilla is grown IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health & bioscience—today announced the opening of its Vanilla Innovation Center in Madagascar, reinforcing vanilla as a strategic and priority tonality for IFF and strengthening its ability to innovate at origin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260508110162/en/ IFF's Vanilla Innovation Center in Madagascar “The opening of the center marks an important step in how we approach vanilla innovation,” said Adam Jańczuk, Ph.D., senior vice president, research, creation and design, Taste, IFF. “By strengthening our presence at origin, we connect science, creativity and sustainability more closely, responding to climate changes, safeguarding quality and creating value across the supply chain.” Located in Toamasina, Madagascar’s principal seaport, near vanilla growing areas and post‑h
ARIS Recognised as a Leader in Gartner® Magic Quadrant™ for Process Intelligence Platforms, Believes This Reinforces Its Role in Enabling Enterprise AI at Scale11.5.2026 14:00:00 CEST | Press release
ARIS, the process context foundation platform for enterprise AI deployment, today announced its recognition as a Leader in the Gartner® Magic Quadrant™ for Process Intelligence Platforms. This is the fourth consecutive year that ARIS has been recognized as a Leader in the report and the company believes it underscores a continued commitment to innovation and growth as enterprises focus on turning AI ambition into measurable business outcomes. While technology has advanced rapidly, companies are struggling to operationalise AI across complex operating models. ARIS sees this recognition by Gartner as a reflection of its strength in delivering a single unified platform for process intelligence, providing the context layer on which G2000 organisations can successfully deploy and scale agentic AI. “AI is moving from experimentation to execution – but many enterprises are finding it difficult to scale,” said Guillaume Bacuvier, CEO of ARIS. “The reason is simple: AI lacks the context it need
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors11.5.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking authorization to expand the use of its Edison® Histotripsy System to include the destruction of kidney (renal) tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511268688/en/ HistoSonics Edison® Histotripsy System This milestone marks a significant step forward in the company’s mission to transform the treatment of solid tumors with a completely non-invasive technology that harnesses focused ultrasound to mechanically liquefy and destroy targeted tissue, reducing the risk of many complications and side effects associated with surgery, radiation, and other common therapies. “This submission is an important milestone in expanding histotripsy beyond the liver and into the kidney, an area where patients and physicians are s
Logistics Reply Named a Visionary in 2026 Gartner® Magic Quadrant™ for Warehouse Management Systems and Ranks #2 for Level 2 and #3 for Level 3 Operations Use Cases in Gartner® Critical Capabilities Report11.5.2026 14:00:00 CEST | Press release
Logistics Reply, the Reply Group company specializing in innovative solutions for supply chain execution, is proud to announce its recognition as a Visionary in the Gartner® Magic Quadrant™ for Warehouse Management Systems for the seventh consecutive year, as its global team of warehouse technology professionals continues to drive innovation that puts customers first. Additionally, Logistics Reply for its LEA Reply™ WMS is recognized in the 2026 Gartner® Critical Capabilities for Warehouse Management Systems report where it ranked #2 for Level 2 Warehouse Operations and #3 for Level 3 Warehouse Operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511344452/en/ We believe these important recognitions underscore Logistics Reply's commitment to delivering intelligent, flexible and scalable warehouse execution solutions for enterprise customers around the world. For us, our placement in the Visionaries Quadrant reflects
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom